September 19, 2005, 7:30pm - 9:30pm
UCSF, Mission Bay Campus Genentech Hall

Speakers
Antoun Nabhan, Principal, Sagamore Bioventures
Bruce Cohen, CEO, Cellerant Therapeutics
Stacy Taylor, Partner, Foley & Lardner
Rik Derynck, Professor, UCSF Developmental and Stem Cell Biology Program
Janet Whitley, Senior, Program Manager, FDA Office of Orphan Products Development

Moderator
Paul Smaglik, Editor, NatureJobs

MC
Jonathan Dickstein, Attorney, Morrison and Forrester

Speaker Presentations
Play Clip

• Jonathan Dickstein
• Rik Derynck
• Stacy Taylor
• Janet Whitley
• Bruce Cohen
• Antoun Nabhan

Questions & Answers

Question: What is needed to take the promise and dreams affiliated with Stem Cell Technologies into the clinic and translated into cures?

• Entire panel, response

Question: What are the parallels with gene patents and stem cell patents with the commercialization of products? Specifically addressing reach through rights and comparisons between the technologies.

• Stacy Taylor

Question: When can we expect products from these technologies? What is the necessary lead time from R&D to the clinic?

• Rik Derynck and Bruce Cohen

Question: What are the early products that we can expect? What is low hanging fruit?

• Bruce Cohen, Rik Derynck, Janet Whitley, and Stacy Taylor

Question: Will the Thompson-WARF patent stand up to legal challenges?

• Stacy Taylor

Question: How is Cellerant planning on ensuring the potency of their products?

• Bruce Cohen and Antoun Nabhan

Question: Please expand on what you think the intent how the Prop 71 monies were to be deployed to support stem cell research.

• Bruce Cohen and Antoun Nabhan